| B60 | Assessing parental choice of lopinavir/ritonavir granules intake to improve child adherence at Baylor-Mwanza, Tanzania | E-poster | Drug formulations for infants and children |
| B60 | Acceleration of pediatric ART regimen optimization during COVID-19 epidemic using self-learning for health care workers in Malawi | E-poster | Drug formulations for infants and children |
| B60 | Proof of principle oral dissolvable strip formulation for pediatric ARV prophylaxis | E-poster | Drug formulations for infants and children |
| B60 | Caregivers perception on paedriatic lopinavir/ritonavir formulations for HIV-infected children at Baylor Clinic, Mwanza, Tanzania | E-poster | Drug formulations for infants and children |
| B60 | Low viral suppression in children < 3 years old on two protease inhibitor formulations in Kenya, 2015-2019 | E-poster | Drug formulations for infants and children |
| B6 | Evaluation of new high-throughput platforms for the quantification of HIV-1 RNA in plasma to support scale-up of viral load testing in low- and middle-income countries | On-demand oral abstract session | Viral load and CD4 measurement |
| B6 | More frequent viral load testing, with point-of-care tests has no impact on viral suppression in postpartum HIV-positive women in a randomized controlled trial in 2 clinics in Johannesburg, South Africa | Oral abstract session with live Q&A | Viral load and CD4 measurement |
| B6 | Expanding HIV-1 VL PT programs using a simple innovative technology | E-poster | Viral load and CD4 measurement |
| B6 | Improving viral load testing coverage among children and adults during the COVID-19 pandemic using a quality improvement approach at Baylor College of Medicine Children's Foundation HIV Clinic, Kampala, Uganda | E-poster | Viral load and CD4 measurement |
| B6 | A multipronged strategy to improve viral load testing coverage in Liberia | E-poster | Viral load and CD4 measurement |